uniQure NV has reached an agreement with the US Food and Drug Administration to proceed with a marketing authorisation application for its gene therapy for Huntington’s disease, a rare, inherited neurodegenerative disorder. The application is expected to be filed in the third quarter of this year, the company announced on 17 June.
Ona Therapeutics SL, a 2019 spin-out from a Spanish research institute and foundation, has raised $86.6 million from venture capitalists to advance a portfolio of early-stage antibody-drug conjugates (ADCs) for refractory cancers. The Series B round was co-led by Columbus Venture Partners of Spain and Mérieux Equity Partners of France. They were joined by the existing Spain-based investors Alta Life Sciences and Asabys Partners and Bpifrance, the French public investment bank.
GSK Plc is to acquire the US oncology developer Nuvalent Inc for $10.6 billion, giving it two late-stage products for non-small cell lung cancer to complement its own Phase 3 antibody-drug conjugate (ADC) for a different lung cancer. The deal, which will be financed with new and existing debt facilities, also gives the UK company a third lung cancer drug in Phase 1 and a preclinical portfolio of undisclosed cancer assets.
Research Strategy
Meeting the challenge of Parkinson's disease
By Henri Huttunen
Regenerative Medicine
Tissue repair for venous disease
By Petter Björquist
Commentary
Asia drives trials but its data must travel too
By Femida Gwadry-Sridhar
Research Strategy
How ligand-conjugated vectors can improve treatment
By Lolita Petit
Company News - Financing
$2.1 billion for Isomorphic Labs
Public Health
WHO responds to Ebola outbreak
